The potential biomarkers to identify the development of steatosis in hyperuricemia

PLoS ONE

Volumn 11, Issue 2, 2016, Pages

  Tan, Yong ^a   Liu, Xinru ^b   Zhou, Ke ^c   He, Xiaojuan ^a   Lu, Cheng ^a   He, Bing ^d   Niu, Xuyan ^a   Xiao, Cheng ^e   Xu, Gang ^d   Bian, Zhaoxiang ^d   Zu, Xianpeng ^b   Zhang, Ge ^d   Zhang, Weidong ^b   Lu, Aiping ^a,d,f  

^a INSTITUTE OF CHINESE MATERIA MEDICA   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c HUNAN UNIVERSITY OF CHINESE MEDICINE   (China)

^d HONG KONG BAPTIST UNIVERSITY   (Hong Kong)

^e CHINA JAPAN FRIENDSHIP HOSPITAL   (China)

^f E institute of Shanghai Municipal Education Commission   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CHOLESTEROL ESTER; INOSINE; LIVER X RECEPTOR; PHOSPHATIDIC ACID; PHOSPHOLIPASE; PURINE NUCLEOTIDE; RETINOID X RECEPTOR;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HUMAN; HYPERURICEMIA; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOLECULAR PATHOLOGY; NONALCOHOLIC FATTY LIVER; REPRODUCIBILITY; TIME OF FLIGHT MASS SPECTROMETRY; BLOOD; CHINA; COMPLICATION; DIAGNOSTIC IMAGING; ECHOGRAPHY; MATRIX-ASSISTED LASER DESORPTION-IONIZATION MASS SPECTROMETRY; METABOLISM; METABOLOME; METABOLOMICS; NON-ALCOHOLIC FATTY LIVER DISEASE; PROCEDURES; QUESTIONNAIRE;

ADULT; BIOMARKERS; CHINA; CHROMATOGRAPHY, LIQUID; DISEASE PROGRESSION; FEMALE; HUMANS; HYPERURICEMIA; MALE; METABOLIC NETWORKS AND PATHWAYS; METABOLOME; METABOLOMICS; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; REPRODUCIBILITY OF RESULTS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; SURVEYS AND QUESTIONNAIRES; ULTRASONOGRAPHY;

EID: 84960510131     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0149043     Document Type: Article

References (51)

1. Voruganti VS, Franceschini N, Haack K, Laston S, MacCluer JW, Umans JG, et al. Replication of the effect of SLC2A9 genetic variation on serum uric acid levels in American Indians. Eur J Hum Genet. 2014; 22(7): 938-943. doi: 10.1038/ejhg.2013.264 PMID: 24301058
2. Matsuo H, Nakayama A, Sakiyama M, Chiba T, Shimizu S, Kawamura Y, et al. ABCG2 dysfunction causes hyperuricemia due to both renal urate underexcretion and renal urate overload. Sci Rep. 2014; 4: 3755. doi: 10.1038/srep03755 PMID: 24441388
3. Cai W, Wu X, Zhang B, Miao L, Sun YP, Zou Y, et al. Serum uric acid levels and non-alcoholic fatty liver disease in Uyghurand Han ethnic groups in northwestern China. Arq Bras Endocrinol Metabol. 2013; 57(8): 617-622. PMID: 24343630
4. Lee JW, Cho YK, Ryan M, Kim H, Lee SW, Chang E, et al. Serum uric Acid as a predictor for the development of nonalcoholic Fatty liver disease in apparently healthy subjects: a 5-year retrospective cohort study. Gut Liver. 2010; 4(3): 378-383. doi: 10.5009/gnl.2010.4.3.378 PMID: 20981217
5. Kuo CF, Yu KH, Luo SF, Chiu CT, Ko YS, Hwang JS, et al. Gout and risk of non-alcoholic fatty liver disease. Scand J Rheumatol. 2010; 39(6): 466-471. doi: 10.3109/03009741003742797 PMID: 20560813
6. Sirota JC, McFann K, Targher G, Johnson RJ, Chonchol M, Jalal DI. Elevated serum uric acid levels are associated with non-alcoholic fatty liver disease independently of metabolic syndrome features in the United States: Liver ultrasound data from the National Health and Nutrition Examination Survey. Metabolism. 2013; 62(3): 392-399. doi: 10.1016/j.metabol.2012.08.013 PMID: 23036645
7. Xie Y, Wang M, Zhang Y, Zhang S, Tan A, Gao Y, et al. Serum uric acid and non-alcoholic fatty liver disease in non-diabetic Chinese men. PLOS One. 2013; 8(7): e67152. doi: 10.1371/journal.pone.0067152 PMID: 23935829
8. Petta S, Cammà C, Cabibi D, Di Marco V, Craxì A. Hyperuricemia is associated with histological liver damage in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2011; 34(7): 757-766. doi: 10.1111/j.1365-2036.2011.04788.x PMID: 21790685
9. Vos MB, Colvin R, Belt P, Molleston JP, Murray KF, Rosenthal P, et al. Correlation of vitamin E, uric acid, and diet composition with histologic features of pediatric NAFLD. J Pediatr Gastroenterol Nutr. 2012; 54(1): 90-96. doi: 10.1097/MPG.0b013e318229da1a PMID: 22197855
10. Katsiki N, Athyros VG, Karagiannis A, Mikhailidis DP. Hyperuricaemiaand non-alcoholic fatty liver disease (NAFLD): a relationship with implications for vascular risk? Curr Vasc Pharmacol. 2011; 9(6): 698-705. PMID: 21388346
11. Lee YJ, Cho S, Kim SR. A possible role of serum uric acid as a marker of metabolic syndrome. Intern Med J. 2014; 44(12a): 1210-1216. doi: 10.1111/imj.12588 PMID: 25228498
12. Csupor D, Borcsa B, Heydel B, Hohmann J, Zupkó I, Ma Y, et al. Comparison of a specific HPLC determination of toxic aconite alkaloids in processed Radix aconiti with a titration method of total alkaloids. Pharm Biol. 2011; 49(10): 1097-1101. doi: 10.3109/13880209.2011.595011 PMID: 21936629
13. Bao Y, Yang F, Yang X. CE-electrochemiluminescencewith ionic liquid for the facile separation and determination of diester-diterpenoid aconitum alkaloids in traditional Chinese herbal medicine. Electrophoresis. 2011; 32(12): 1515-1521. doi: 10.1002/elps.201100040 PMID: 21692082
14. Llorach R, Garrido I, Monagas M, Urpi-Sarda M, Tulipani S, Bartolome B, et al. Metabolomics study of human urinary metabolome modifications after intake of almond (Prunus dulcis (Mill.) D.A. Webb) skin polyphenols. J Proteome Res. 2010; 9(11): 5859-5867. doi: 10.1021/pr100639v PMID: 20853910
15. Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, et al. Metabolomic profiles delineate potential roleforsarcosinein prostate cancer progression. Nature. 2009; 457(7231): 910-914. doi: 10.1038/nature07762 PMID: 19212411
16. Zhang A, Sun H, Wang Z, Sun W, Wang P, Wang X. Metabolomics: towards understanding traditional Chinese medicine. Planta Med. 2010; 76(17): 2026-2035. doi: 10.1055/s-0030-1250542 PMID: 21058239
17. Zhang Z, Lu C, Liu X, Su J, Dai W, Yan S, et al. Global and targeted metabolomics reveal that Bupleuro toxin, a toxic type of polyacetylene, induces cerebral lesion by inhibiting GABA receptor in mice. J Proteome Res. 2014; 13(2): 925-933. doi: 10.1021/pr400968c PMID: 24328154
18. Tsutsui H, Maeda T, Min JZ, Inagaki S, Higashi T, Kagawa Y, et al. Biomarker discovery in biological specimens (plasma, hair, liver and kidney) of diabetic mice based upon metabolite profiling using ultra performance liquid chromatography with electrospray ionization time-of-flight mass spectrometry. Clin Chim Acta. 2011; 412(11-12): 861-872. doi: 10.1016/j.cca.2010.12.023 PMID: 21185819
19. Xie C, Zhong D, Yu K, Chen X. Recent advances in metabolite identification and quantitative bioanaly sis by LC-Q-TOF MS. Bioanalysis. 2012; 4(8): 937-959. doi: 10.4155/bio.12.43 PMID: 22533568
20. Zhao X, Long Z, Dai J, Bi K, Chen X. Identification of multiple constituents in the traditional Chinese medicine formula Zhi-zi-chi decoction and rat plasma after oral administration by liquid chromatography coupled to quadrupole time-of-flight tandem mass spectrometry. Rapid Commun Mass Spectrom. 2012; 26(20): 2443-2453. doi: 10.1002/rcm.6360 PMID: 22976211
21. Dai HF, Shen Z, Yu CH, Zhang XC, Li YM. Epidemiology of fatty liver in an islander population of China: a population-based case-control study. Hepatobiliary Pancreat Dis Int. 2008; 7(4): 373-378. PMID: 18693172
22. Hernaez R, Lazo M, Bonekamp S, Kamel I, Brancati FL, Guallar E, et al. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. Hepatology. 2011; 54(3): 1082-1090. doi: 10.1002/hep.24452 PMID: 21618575
23. Tan Y, Li J, Liu X, Ko J, He X, Lu C, et al. Deciphering the differential toxic responses of Radix aconiti lateralis praeparata in healthy and hydrocortisone-pretreated rats based on serum metabolic profiles. J Proteome Res. 2013; 12(1): 513-524. doi: 10.1021/pr300965d PMID: 23205644
24. Athenstaedt K, Daum G. Phosphatidic acid, a key intermediate in lipid metabolism. Eur J Biochem. 1999; 266(1): 1-16. PMID: 10542045
25. Kent C. Eukaryotic phospholipid biosynthesis. Annu Rev Biochem. 1995; 64: 315-43. PMID: 7574485
26. Delon C, Manifava M, Wood E, Thompson D, Krugmann S, Pyne S, et al. Sphingosine kinase 1 is an intracellular effector of phosphatidic acid. J BiolChem. 2004; 279(43): 44763-44774. PMID: 15310762
27. Chalimoniuk M. Secretory phospholipase A2 and its role in oxidative stress and inflammation. Postepy Biochem. 2012; 58(2): 204-208. PMID: 23214144 [Article in Polish]
28. Sun GY, Xu J, Jensen MD, Yu S, Wood WG, González FA, et al. Phospholipase A2 in astrocytes: responses to oxidative stress, inflammation, and G protein-coupled receptor agonists. Mol Neurobiol. 2005; 31(1-3): 27-41. PMID: 15953810
29. Rosenson RS, Stafforini DM. Modulation of oxidative stress, inflammation, and atherosclerosis by lipo protein-associated phospholipase A2. J Lipid Res. 2012; 53(9): 1767-1782. doi: 10.1194/jlr.R024190 PMID: 22665167
30. Shen W, Martinez K, Chuang CC, McIntosh M. The phospholipase C inhibitor U73122 attenuates trans-10, cis-12 conjugated linoleic acid-mediated inflammatory signaling and insulin resistance in human adipocytes. J Nutr. 2013; 143(5): 584-590. doi: 10.3945/jn.112.173161 PMID: 23468551
31. Suchard SJ, Nakamura T, Abe A, Shayman JA, Boxer LA. Phospholipase D-mediated diradylglycerol formation coincides with H2O2 and lactoferrin release in adherent human neutrophils. J Biol Chem. 1994; 269(11): 8063-8068. PMID: 8132530
32. Tappia PS, Dent MR, Dhalla NS. Oxidative stress and redox regulation of phospholipase D in myocardial disease. Free Radic Biol Med. 2006; 41(3): 349-361. PMID: 16843818
33. Kurtz TA, Fineberg NS, Considine RV, Deeg MA. Insulin resistance is associated with increased serum levels of glycosylphosphatidylinositol-specific phospholipase D. Metabolism. 2004; 53(2): 138-139. PMID: 14767861
34. Hediger MA, Johnson RJ, Miyazaki H, Endou H. Molecular physiology of urate transport. Physiology (Bethesda). 2005; 20: 125-133. PMID: 15772301
35. Abuja PM Ascorbate prevents prooxidant effects of urate in oxidation of human low density lipoprotein. FEBS Lett. 1999; 446(2-3): 305-308. PMID: 10100863
36. Patterson RA, Horsley ET, Leake DS. Prooxidant and antioxidant properties of human serum ultrafil trates toward LDL: important role of uric acid. J Lipid Res. 2003; 44(3): 512-521. PMID: 12562831
37. Ghaemi-Oskouie F, Shi Y. The role of uric acid as an endogenous danger signal in immunity and inflammation. Curr Rheumatol Rep. 2011; 13(2): 160-166. PMID: 21234729 doi: 10.1007/s11926-011-0162-1
38. Hayden MR, Tyagi SC. Uric acid: A new look at an old risk marker for cardiovascular disease, metabolic syndrome, and type 2 diabetes mellitus: The urate redox shuttle. Nutr Metab (Lond). 2004; 1(1): 10. PMID: 15507132.
39. García-Ruiz I, Rodríguez-Juan C, Díaz-Sanjuan T, del Hoyo P, Colina F, Muñoz-Yagüe T, et al. Uric acid and anti-TNF antibody improve mitochondrial dysfunction in ob/ob mice. Hepatology. 2006; 44(3): 581-591. PMID: 16941682
40. Albano E, Mottaran E, Occhino G, Reale E, Vidali M. Review article: role of oxidative stress in the progression of non-alcoholic steatosis. Aliment Pharmacol Ther. 2005; 22 Suppl 2: 71-73. PMID: 16225478
41. Nieto FJ, Iribarren C, Gross MD, Comstock GW, Cutler RG. Uric acid and serum antioxidant capacity: a reaction to atherosclerosis? Atherosclerosis. 2000; 148(1): 131-139. PMID: 10580179
42. Waring WS, Webb DJ, Maxwell SR. Systemic uric acid administration increases serum antioxidant capacity in healthy volunteers. J Cardiovasc Pharmacol. 2001; 38(3): 365-371. PMID: 11486241
43. Dawson J, Walters M. Uric acid and xanthine oxidase: future therapeutic targets in the prevention of cardiovascular disease? Br J Clin Pharmacol. 2006; 62(6): 633-644. PMID: 21894646
44. Park SH, Kim BI, Yun JW, Kim JW, Park DI, Cho YK, et al. Insulin resistance and C-reactive protein as independent risk factors for non-alcoholic fatty liver disease in non-obese Asian men. J Gastroenterol Hepatol. 2004; 19(6): 694-698. PMID: 15151626
45. Vuorinen-Markkola H, Yki-Järvinen H. Hyperuricemia and insulin resistance. J Clin Endocrinol Metab. 1994; 78(1): 25-29. PMID: 8288709
46. Pagano G, Pacini G, Musso G, Gambino R, Mecca F, Depetris N, et al. Nonalcoholicsteatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. Hepatology. 2002; 35(2): 367-372. PMID: 11826410
47. Petta S, Muratore C, Craxì A. Non-alcoholic fatty liver disease pathogenesis: the present and the future. Dig Liver Dis. 2009; 41(9): 615-625. doi: 10.1016/j.dld.2009.01.004 PMID: 19223251
48. Modan M, Halkin H, Karasik A, Lusky A. Elevated serum uric acid - a facet of hyperinsulinaemia. Dia betologia. 1987; 30(9): 713-718. PMID: 3322912
49. Kurotani K, Sato M, Ejima Y, Nanri A, Yi S, Pham NM, et al. High levels of stearic acid, palmitoleicacid, and dihomo-gamma-linolenic acid and low levels of linoleic acid in serum cholesterol ester are associated with high insulin resistance. Nutr Res. 2012; 32(9): 669-675 e3. doi: 10.1016/j.nutres.2012.07.004 PMID: 23084639
50. Baranowski M. Biological role of liver X receptors. J Physiol Pharmacol. 2008; 59 Suppl 7: 31-55. PMID: 19258656
51. Ahn SB, Jang K, Jun DW, Lee BH, Shin KJ. Expression of liver X receptor correlates with intrahepatic inflammation and fibrosis in patients with nonalcoholic fatty liver disease. Dig Dis Sci. 2014; 59(12): 2975-2982. doi: 10.1007/s10620-014-3289-x PMID: 25102981